Docteur Zoubir DJERADA

Publications représentatives

1.    Pharmacologie fondamentale et transrationnelle : approches pharmacologiques visant à identifier les mécanismes mis en jeu lors des ischémies (cardiaque, rénale, membre inférieurs), lors de l’insuffisance cardiaque et leurs interactions avec la fonction endothéliale. 

1: Djerada Z, Feliu C, Richard V, Millart H. Current knowledge on the role of P2Y receptors in cardioprotection against ischemia-reperfusion. Pharmacol Res. 2017 Apr;118:5-18. (IF = 4.897)

2: Wils J, Djerada Z*, Roca F, Duflot T, Iacob M, Remy-Jouet I, Joannides R, Bellien J. Alteration in the availability of epoxyeicosatrienoic acids contributes with NO to the development of endothelial dysfunction in conduit arteries during aging. Atherosclerosis. 2018 Aug;275:239-245. (IF= 4.467)
* Co-premier auteur

3: Bonnard B, Pieronne-Deperrois M, Djerada Z*, Elmoghrabi S, Kolkhof P, Ouvrard-Pascaud A, Mulder P, Jaisser F, Messaoudi S. Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice. J Mol Cell Cardiol. 2018 Aug;121:124-133. (IF= 5.296)
*co-deuxième auteur.

4 :Feliu C, Peyret H, Poitevin G, Cazaubon Y, Oszust F, Nguyen P, Millart H, Djerada Z. Complementary Role of P2 and Adenosine Receptors in ATP Induced-Anti-Apoptotic Effects Against Hypoxic Injury of HUVECs. Int J Mol Sci. 2019 Mar 22;20(6). pii: E1446. doi: 10.3390/ijms20061446. (IF= 3.7)

2.    Pharmacologie clinique : approche de modélisation pharmacocinétique-pharmacodynamique dans la personnalisation des traitements.
1: Djerada Z, Feliu C, Cazaubon Y, Smati F, Gomis P, Guerrot D, Charbit B, Fernandes O, Malinovsky JM. Population Pharmacokinetic-Pharmacodynamic Modeling of Ropivacaine in Spinal Anesthesia. Clin Pharmacokinet. 2018 Sep;57(9):1135-1147. (IF=5.216)

2: Cazaubon Y, Mauprivez C, Feliu C, Binet L, Oget O, Gozalo C, Djerada Z. Population pharmacokinetics of articaine with 1:200,000 epinephrine during third molar surgery and simulation of high-dose regimens. Eur J Pharm Sci. 2018 Mar 1;114:38-45. (IF= 3.756)

3: Djerada Z, Fournet-Fayard A, Gozalo C, Lelarge C, Lamiable D, Millart H, Malinovsky JM. Population pharmacokinetics of nefopam in elderly, with or without renal impairment, and its link to treatment response. Br J Clin Pharmacol. 2014 Jun;77(6):1027-38. (IF= 3.878)

4 : Cazaubon Y, Talineau Y, Feliu C, Konecki C, Russello J, Mathieu O and Djerada Z. Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at 3 Months?. Pharmaceutics 2019, 11, accepted. (IF :4.77)

3.    Pharmacologie biologique : développement et validation de méthodes de dosage avec les techniques séparatives couplées à la spectrométrie de masse.
1: Feliu C, Cazaubon Y, Guillemin H, Vautier D, Oget O, Millart H, Gozalo C, Djerada Z. Therapeutic drug monitoring of mitotane: Analytical assay and patient follow-up. Biomed Chromatogr. 2017 Nov;31(11). 

2: Feliu C, Millart H, Guillemin H, Vautier D, Binet L, Fouley A, Djerada Z. Validation of a fast UPLC-MS/MS method for quantitative analysis of opioids, cocaine, amphetamines (and their derivatives) in human whole blood. Bioanalysis.  2015;7(20):2685-700. (IF=2.813)

3: Djerada Z, Feliu C, Tournois C, Vautier D, Binet L, Robinet A, Marty H, Gozalo C, Lamiable D, Millart H. Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology. J Pharm Biomed Anal. 2013 Dec;86:100-11. (IF=2.831)

Publications
https://scholar.google.com/scholar?start=0&q=djerada&hl=fr&as_sdt=0,5
https://www.ncbi.nlm.nih.gov/pubmed/?term=djerada